Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 11/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.53 |
| ▸ | BLM | P54132 | 3/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | APEX1 | P27695 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30979648 | 0.92 | POLB (0.66) | POLBSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL23867479 | 0.89 | POLB (0.49) | POLBSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL23867576 | 0.86 | LMNA (0.52) | POLBSMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL31094221 | 0.84 | LMNA (0.49) | POLBSMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL23867475 | 0.84 | POLB (0.55) | POLBSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL23867508 | 0.83 | ALDH1A1 (0.55) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL30234578 | 0.82 | POLB (0.52) | POLBSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL23867477 | 0.82 | POLB (0.52) | POLBSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL23867649 | 0.81 | ALDH1A1 (0.52) | POLBSMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL31094238 | 0.81 | SLC2A1 (0.50) | POLBSMN1; SMN2MAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338898-A | Small molecule inhibitors of oncogenic CHD1L with preclinical anti-colorectal cancer activity | 科罗拉多州立大学董事会（法人团体） | 2024-07-12 | — | — | CN | disclosed |
| WO-2023055763-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTRAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230103444-A1 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | UNITED STATES GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| EP-4127209-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115667553-A | Small molecule inhibitors of oncogenic CHD1L with preclinical activity against colorectal cancer | 科罗拉多州立大学董事会法人团体 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021195279-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021195279-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103444-A1 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | CHD1L, CHD1, CHD9 | POLB 2074/4885SMN1; SMN2 3457/4885RAB9A 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.